Philip J. Moos, PhD

Languages

  • English

Academic Information

  • Departments: Pharmacology and Toxicology - Associate Professor
  • Cancer Center Programs: Cell Response & Regulation

Academic Office Information

  • 801-585-5952
  • L.S. Skaggs Hall
    30 S 2000 E
    Salt Lake City, UT 84112

Academic Bio

Phillip Moos, PhD, is an assistant professor in the Department of Pharmacology and Toxicology at the University of Utah and a member of the Cell Response and Regulation Program at Huntsman Cancer Institute.

Moos studies the reduction-oxidation relationship between inflammation and cancer. He is particularly interested in the role of selenoproteins in the origin of cancer. He also studies the role of thioredoxin reductase-1 in melanoma, and nanoparticles found in consumer products as potential initiators of inflammatory responses and cancer.

Moos received a bachelor's degree from the University of Colorado, Boulder, and a PhD from Kansas State University.

Education History

Type School Degree
Postdoctoral Fellowship Pharmacia & Upjohn, Inc.
Molecular Biology
Postdoctoral Fellow
Postdoctoral Fellowship Kansas State University
Postdoctoral Fellow
Doctoral Training Kansas State University
Biology
Ph.D.
Graduate Training University of Colorado
Aerospace Engineering
M.S.
Undergraduate University of Colorado
Aerospace Engineering
B.S.

Selected Publications

Journal Article

  1. Yazdimamaghani M, Moos PJ, Ghandehari H (2019). Time- and dose-dependent gene expression analysis of macrophage response as a function of porosity of silica nanoparticles. Nanomedicine, 21, 102041.
  2. Yazdimamaghani M, Moos PJ, Dobrovolskaia MA, Ghandehari H (2018). Genotoxicity of amorphous silica nanoparticles: Status and prospects. Nanomedicine, 16, 106-125.
  3. Kwon SH, Li L, Terry CM, Shiu YT, Moos PJ, Milash BA, Cheung AK, Blumenthal DK (2018). Differential gene expression patterns in vein regions susceptible versus resistant to neointimal hyperplasia. Physiol Genomics, 50(8), 615-627.
  4. Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, Reddy CB, Boltax JP, Li DY, Moos PJ, Gray JW, Heiser LM, Buys SS, Cohen AL, Johnson WE, Quinlan AR, Marth G, Werner TL, Bild AH (2018). Publisher Correction: Combating subclonal evolution of resistant cancer phenotypes. Nat Commun, 9(1), 572.
  5. Yazdimamaghani M, Moos PJ, Ghandehari H (2017). Global gene expression analysis of macrophage response induced by nonporous and porous silica nanoparticles. Nanomedicine, 14(2), 533-545.
  6. Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, Reddy CB, Boltax JP, Li DY, Moos PJ, Gray JW, Heiser LM, Buys SS, Cohen AL, Johnson WE, Quinlan AR, Marth G, Werner TL, Bild AH (2017). Combating subclonal evolution of resistant cancer phenotypes. Nat Commun, 8(1), 1231.
  7. Piccolo SR, Hoffman LM, Conner T, Shrestha G, Cohen AL, Marks JR, Neumayer LA, Agarwal CA, Beckerle MC, Andrulis IL, Spira AE, Moos PJ, Buys SS, Johnson WE, Bild AH (2016). Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. Mol Syst Biol, 12(3), 860.